NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type2 Diabetes Mellitus
Date of first enrollment	10/04/2009
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : KRP-104 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : twice a day,12weeks control material(s) Generic name etc : KRP-104,Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : twice a day,12weeks

Outcome(s)

Primary Outcome	HbA1c change from baseline on HbA1c at 12 weeks
Secondary Outcome	FPG,glycoalbumin,insulin etc. change from baseline on FPG at 12 weeks change from baseline on glycoalbumin at 12 weeks change from baseline on insulin at 12 weeks etc.

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 74age old
Gender	Both
Include criteria	Inclusion Criteria; -Diagnosis of type 2 diabetes -Outpatients etc.
Exclude criteria	Exclusion criteria; -Diagnosis of type 1 diabetes -Patients with malignant tumor -Patients with severe hepatic dysfunction -Patients with severe renal dysfunction -Patients with severe blood dyscraaia -Patients with severe cardiovascular or pulmonary dysfunction etc.